AYTU

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Peers: CPHI RMTI TXMD BGM ZYBT CPIX CTOR SCYX DERM SCLX

Index	-
Market Cap	23.61M
Enterprise Value	19.84M
Income	-34.05M
Sales	56.60M
Book/sh	3.27
Cash/sh	2.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	83
IPO	Sep 24, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	0.42
P/B	0.67
P/C	0.88
P/FCF	14.40
EV/EBITDA	-
EV/Sales	0.35
Quick Ratio	1.00
Current Ratio	1.12
Debt/Eq	0.65
LT Debt/Eq	0.30
Option/Short	No / Yes

EPS (ttm)	-4.58
EPS next Y	-0.08
EPS next Q	-0.29
EPS this Y	53.10%
EPS next Y	92.45%
EPS next 5Y	-
EPS past 3/5Y	88.66% 48.61%
Sales past 3/5Y	-11.78% 19.16%
EPS Y/Y TTM	-2264.65%
Sales Y/Y TTM	-18.24%
EPS Q/Q	-353.08%
Sales Q/Q	-32.74%
Earnings	May 13 AMC
EPS/Sales Surpr.	-19.56% 2.97%

Insider Own	8.98%
Insider Trans	0.00%
Inst Own	36.55%
Inst Trans	1.82%
ROA	-28.93%
ROE	-97.42%
ROIC	-74.66%
Gross Margin	60.09%
Oper. Margin	-12.19%
Profit Margin	-60.17%
SMA20	0.43%
SMA50	-4.85%
SMA200	-7.27%
Trades

Shs Outstand	10.73M
Shs Float	9.77M
Short Float	3.63%
Short Ratio	8.85
Short Interest	0.35M
52W High	3.07 -28.22%
52W Low	1.65 33.33%
Volatility	4.00% 4.88%
ATR (14)	0.10
RSI (14)	48.01
Beta	0.24
Rel Volume	0.21
Avg Volume	40.06K
Volume	6,014

Perf Week	-2.22%
Perf Month	-1.79%
Perf Quarter	-15.38%
Perf Half Y	-13.04%
Perf YTD	-15.38%
Perf Year	4.76%
Perf 3Y	47.65%
Perf 5Y	-97.84%
Perf 10Y	-100.00%
Recom	1.00
Target Price	9.50
Prev Close	2.17
Price	2.20
Change	1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Initiated	Lake Street	Buy	$8
Jun-30-25	Initiated	Ascendiant Capital Markets	Buy	$12
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$11
May-29-20	Initiated	H.C. Wainwright	Buy	$3

Jun-01-26 04:15PM	Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 (ACCESSWIRE) -6.11%
May-18-26 04:05PM	Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 (ACCESSWIRE)
May-14-26 08:30AM	Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary (Moby)
01:02AM	Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ... (GuruFocus.com)
May-13-26 04:05PM	Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results (ACCESSWIRE)
04:05PM	Loading…
May-06-26 04:05PM	Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 (ACCESSWIRE)
Feb-04-26 12:02AM	Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -10.31%
Feb-03-26 06:15PM	Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:37PM	Aytu BioPharma AYTU Q2 2026 Earnings Transcript (Motley Fool)
04:05PM	Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results (ACCESSWIRE)
Feb-02-26 07:20AM	Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Result (GuruFocus.com)
05:37AM	New Strong Sell Stocks for February 2nd (Zacks)
Jan-27-26 04:05PM	Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 (ACCESSWIRE)
Jan-20-26 04:05PM	Aytu BioPharma Recaps Investor Day Held on January 20, 2026 (ACCESSWIRE)
09:00AM	Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA (ACCESSWIRE)
04:15PM	Loading…
Jan-13-26 04:15PM	Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 (ACCESSWIRE)
Jan-12-26 08:00AM	Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City (ACCESSWIRE)
Dec-18-25 09:00AM	Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City (ACCESSWIRE)
Dec-15-25 09:00AM	Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults (ACCESSWIRE)
Nov-24-25 04:05PM	Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference (ACCESSWIRE)
Nov-14-25 12:02AM	Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... (GuruFocus.com)
Nov-13-25 05:20PM	Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results (ACCESSWIRE)
Nov-12-25 09:10AM	Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:38AM	Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-06-25 05:35PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -5.14%
Nov-05-25 04:05PM	Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 (ACCESSWIRE)
Oct-28-25 09:00AM	Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) (ACCESSWIRE)
Oct-13-25 08:42AM	New Strong Sell Stocks for Oct. 13th (Zacks)
Oct-10-25 09:00AM	Aytu BioPharma to Present at Upcoming October 2025 Conferences (ACCESSWIRE) -5.98%
08:00AM	Loading…
Sep-25-25 08:00AM	11 Company Presentations Today at The MicroCap Rodeo Conference (ACCESSWIRE) -9.71%
Sep-24-25 04:15PM	Aytu BioPharma to Present at Upcoming September 2025 Conferences (ACCESSWIRE) -17.93%
03:02AM	Aytu BioPharma Inc (AYTU) Q4 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Sep-23-25 04:05PM	Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) (ACCESSWIRE)
Sep-16-25 04:05PM	Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025 (ACCESSWIRE)
Aug-27-25 05:20PM	Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Jul-22-25 11:03AM	Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition (Insider Monkey) +7.81%
Jul-02-25 10:05PM	Aytu Boosts Liquidity with Eclipse Loan Extension (Insider Monkey)
Jun-25-25 08:00AM	Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) (ACCESSWIRE) +5.39%
Jun-23-25 08:00AM	Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) (ACCESSWIRE)
Jun-09-25 04:30PM	Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan (ACCESSWIRE) +5.50%
07:30AM	Aytu BioPharma to commercialise Exxua for MDD in the US (Pharmaceutical Technology)
Jun-06-25 08:01AM	Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock (ACCESSWIRE) +34.23%
08:00AM	Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States (ACCESSWIRE)
May-15-25 03:17AM	Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +91.85%
May-14-25 04:05PM	Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results (ACCESSWIRE)
May-07-25 04:15PM	Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 (ACCESSWIRE)
Apr-21-25 04:05PM	Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 (ACCESSWIRE)
Feb-13-25 08:00AM	Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... (GuruFocus.com)
Feb-12-25 04:03PM	Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results (ACCESSWIRE)
Feb-05-25 05:50PM	Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 (ACCESSWIRE) +6.29%
Jan-06-25 09:00AM	Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (ACCESSWIRE) +5.07%
Dec-05-24 06:32AM	Aytu BioPharma Proposes Settlement in Shareholder Lawsuit (TipRanks)
Dec-03-24 11:45PM	Aytu BioPharma Disclosure Notification (ACCESSWIRE)
Nov-22-24 09:00AM	Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) (ACCESSWIRE) +8.08%
Nov-14-24 02:16AM	Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Historic Quarter with Positive ... (GuruFocus.com) -11.17%
Nov-13-24 04:05PM	Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results (ACCESSWIRE)
Nov-06-24 05:20PM	Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 (ACCESSWIRE)
Oct-14-24 04:15PM	Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE)
Oct-01-24 08:00AM	Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada (ACCESSWIRE)
Sep-27-24 07:40AM	Q4 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -17.16%
Sep-26-24 04:15PM	Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results (ACCESSWIRE) +17.24%
Sep-19-24 05:30PM	Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 (ACCESSWIRE)
Aug-08-24 05:20PM	Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 (ACCESSWIRE)
Aug-06-24 08:00AM	Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations (ACCESSWIRE)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-18-24 08:00AM	Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms (ACCESSWIRE)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile)
May-23-24 09:00AM	Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (ACCESSWIRE)
May-16-24 09:53AM	Q3 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ... (GuruFocus.com)
May-15-24 08:54PM	AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024 (InvestorPlace) -7.83%
04:05PM	Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results (ACCESSWIRE)
May-08-24 04:15PM	Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 (ACCESSWIRE)
Apr-03-24 09:00AM	Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Feb-16-24 08:27AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-15-24 05:49AM	Q2 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-14-24 04:05PM	Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter (ACCESSWIRE) +5.35%
Feb-07-24 04:15PM	Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 (ACCESSWIRE)
Jan-23-24 09:00AM	Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (ACCESSWIRE)
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 08:00AM	Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 (ACCESSWIRE)
Nov-15-23 09:44AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript (Insider Monkey) -22.11%
Nov-14-23 04:05PM	Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results (ACCESSWIRE) +10.11%
Nov-08-23 08:30AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year (ACCESSWIRE)
Nov-07-23 04:15PM	Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023 (ACCESSWIRE) +5.14%
Oct-26-23 08:00AM	Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.82%
Oct-09-23 04:15PM	Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023 (ACCESSWIRE) -8.59%
Sep-28-23 08:18AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript (Insider Monkey) +39.06%
Sep-27-23 04:20PM	Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 (ACCESSWIRE) +16.36%
Sep-21-23 08:25PM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023 (ACCESSWIRE)
Sep-13-23 08:00AM	Aytu BioPharma to Present at LD Micro Main Event XVI Conference (ACCESSWIRE)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly) +10.30%
07:43AM	Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Jul-31-23 08:00AM	Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority (ACCESSWIRE)

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Denver, CO.

CEO & DirectorMr. Joshua R. Disbrow

CFOMr. Ryan J. Selhorn CPA

Chief Business OfficerMr. Jarrett T. Disbrow Ph.D.

Chief Commercial OfficerMr. Greg Pyszczymuka

Vice President of OperationsMs. Margaret Cabano

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Aytu BioPharma Inc

Upgrade your Finviz experience